# A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

> **NCT03657043** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 98 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** tisotumab vedotin

## Key facts

- **NCT ID:** NCT03657043
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657043, "A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03657043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*